-
Stereotaxis and MicroPort EP Receive NMPA Approval for Magbot Magnetic Navigation Ablation Catheter
•
US-based Stereotaxis, Inc. (NYSEAMERICAN: STXS) and its Chinese partner Shanghai MicroPort EP Medtech Co., Ltd. (SHA: 688351, MicroPort EP) have jointly announced the receipt of marketing approval from the National Medical Products Administration (NMPA) of China for their co-developed Magbot magnetic navigation ablation catheter. This approval marks a significant milestone…
-
Genesis RMN Robotic Magnetic Navigation System Approved by China’s NMPA
•
The Genesis RMN cardiac electrophysiological robot magnetic navigation system, represented in China by Shanghai Microport EP Medtech Co., Ltd, (SHA: 688351) has been granted marketing approval by the National Medical Products Administration (NMPA) in China. Global Recognition and Enhanced FeaturesDeveloped by Stereotaxis, the Genesis RMN system has already received approval…
-
Microport EP Medtech’s Cryoablation Catheter and Equipment Approved as Innovative Devices in China
•
Shanghai Microport EP Medtech Co., Ltd has announced that its balloon type cryoablation catheter and cryoablation equipment have been approved for marketing as innovative devices in China. This marks a significant advancement in the treatment of drug-resistant, recurrent, and symptomatic paroxysmal atrial fibrillation, with the devices being the first of…
-
MicroPort Scientific Plans IPO for Subsidiary MicroPort CRM on Hong Kong Stock Exchange
•
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced its intention to spin off its France-based subsidiary, MicroPort Cardiac Rhythm Management Limited (MicroPort CRM), to pursue an initial public offering (IPO) on the Hong Kong Stock Exchange. This move has been confirmed by the bourse, and MicroPort expects…
